These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31595891)

  • 1. An amphipathic cell penetrating peptide aids cell penetration of cyclosporin A and increases its therapeutic effect in an in vivo mouse model for dry eye disease.
    Hyun S; Li L; Yoon KC; Yu J
    Chem Commun (Camb); 2019 Nov; 55(91):13657-13660. PubMed ID: 31595891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion.
    Karn PR; Kim HD; Kang H; Sun BK; Jin SE; Hwang SJ
    Int J Nanomedicine; 2014; 9():3791-800. PubMed ID: 25143728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine Amicellar delivery system for dry eyes.
    Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
    Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.
    Turner K; Pflugfelder SC; Ji Z; Feuer WJ; Stern M; Reis BL
    Cornea; 2000 Jul; 19(4):492-6. PubMed ID: 10928765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perfluorohexyloctane (F
    Chachaj-Brekiesz A; Wnętrzak A; Lipiec E; Kobierski J; Dynarowicz-Latka P
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110564. PubMed ID: 31704647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
    Gehlsen U; Braun T; Notara M; Krösser S; Steven P
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
    Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
    J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of carbenoxolone, an 11β-HSD1 inhibitor, against chemical induced dry eye syndrome.
    Na YJ; Choi KJ; Park SB; Sung HR; Jung WH; Kim HY; Rhee SD; Kim KY
    Apoptosis; 2017 Nov; 22(11):1441-1453. PubMed ID: 28887719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
    Yu Y; Chen D; Li Y; Yang W; Tu J; Shen Y
    Drug Deliv; 2018 Nov; 25(1):888-899. PubMed ID: 29631468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
    Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine.
    Kunert KS; Tisdale AS; Gipson IK
    Arch Ophthalmol; 2002 Mar; 120(3):330-7. PubMed ID: 11879137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT.
    Gao W; Yang X; Lin Z; He B; Mei D; Wang D; Zhang H; Zhang H; Dai W; Wang X; Zhang Q
    J Control Release; 2017 Sep; 261():174-186. PubMed ID: 28662902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
    Liu S; Dozois MD; Chang CN; Ahmad A; Ng DL; Hileeto D; Liang H; Reyad MM; Boyd S; Jones LW; Gu FX
    Mol Pharm; 2016 Sep; 13(9):2897-905. PubMed ID: 27482595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.
    Agarwal P; Scherer D; Günther B; Rupenthal ID
    Int J Pharm; 2018 Mar; 538(1-2):119-129. PubMed ID: 29339249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciclosporin use in dry eye disease patients.
    Ridder WH
    Expert Opin Pharmacother; 2008 Dec; 9(17):3121-8. PubMed ID: 19006483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery.
    Grimaudo MA; Pescina S; Padula C; Santi P; Concheiro A; Alvarez-Lorenzo C; Nicoli S
    Mol Pharm; 2018 Feb; 15(2):571-584. PubMed ID: 29313693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye.
    Lin BW; Huang WL; Wang L; Chen ZM
    J Ocul Pharmacol Ther; 2018 Nov; 34(9):633-641. PubMed ID: 30227093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.